Whole-genome sequencing in healthy people, Mayo Clin Proc, vol.92, pp.159-72, 2017. ,
Cost analysis of whole genome sequencing in German clinical practice, Eur J Health Econ, vol.18, pp.623-656, 2017. ,
Is the $1000 genome as near as we think? A cost analysis of next-generation sequencing ,
, Clin Chem, vol.62, issue.11, pp.1458-64, 2016.
The path to personalized medicine, N Engl J Med, vol.363, pp.301-305, 2010. ,
Comparative optimism in models involving both classical clinical and gene expression information, BMC Bioinformatics, vol.9, p.434, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00428280
Why most published research findings are false, PLoS Med, vol.2, p.124, 2005. ,
Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 Trial (ET), J Clin Oncol, vol.35, pp.402-413, 2017. ,
Evidence-based medicine versus personalized medicine: are they enemies?, J Clin Psychopharmacol, vol.32, pp.153-64, 2012. ,
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics, Genet Med, vol.19, pp.249-55, 2017. ,
Genomic risk prediction of coronary artery disease in 480,000 adults: Implications for primary prevention, J Am Coll Cardiol, vol.72, pp.1883-93, 2018. ,
Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx), Therapie, vol.72, pp.175-83, 2017. ,
,
Implementing pharmacogenomics in Europe: design and implementation strategy of the Ubiquitous Pharmacogenomics Consortium, Clin Pharmacol Ther, vol.101, pp.341-58, 2017. ,
Comment mesure-t-on le bénéfice net d'un traitement ?, Therapie, vol.72, pp.51-61, 2017. ,
Big data" and "open data": What kind of access should researchers enjoy?, 2016. ,
, , vol.71, pp.107-121
, Contribution du Comité consultatif national d'éthique à la révision de la loi de bioéthique, 2018.
Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study, Eur J Hum Genet, vol.26, pp.314-337, 2018. ,
URL : https://hal.archives-ouvertes.fr/halshs-01703194
Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature, Genet Med, vol.20, pp.1122-1152, 2018. ,
The cost-effectiveness of returning incidental findings from next-generation genomic sequencing, Genet Med, vol.17, pp.587-95, 2015. ,
Cost-effectiveness analyses of genetic and genomic diagnostic tests, Nat Rev Genet, vol.19, pp.235-281, 2018. ,
Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation, Health Care Manag Sci, vol.21, pp.204-227, 2018. ,
URL : https://hal.archives-ouvertes.fr/halshs-01526704
, Haute autorité de santé. Guide méthodologique. Choix méthodologique pour l'évaluation économique à la HAS. Octobre, 2011.
Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national ,